Full-Time

Senior/Executive Director

Translational Sciences & Nonclinical Operations

Posted on 6/20/2024

ReCode Therapeutics

ReCode Therapeutics

51-200 employees

Develops genetic medicines with advanced delivery technology

Data & Analytics
Biotechnology

Compensation Overview

$265k - $300kAnnually

+ 100% subsidized premium cost + company 401k contribution + 15 days of company paid holidays + mental health support + FSA + employee discounts at hotspots

Senior

Menlo Park, CA, USA

Requirements
  • Advanced degree in life sciences or medicine (PhD/MD/PharmD preferred)
  • 12+ years of experience in the biopharma industry in non-clinical development
  • Strong understanding of science and drug development
  • Comprehensive knowledge of GLP regulations
  • Background in rare diseases, genetic medicines, gene therapy, and/or lipid nanoparticles a plus
  • Strong knowledge of global regulatory requirements
  • Excellent communication and interpersonal skills
  • Strong leadership skills
Responsibilities
  • Oversee and provide strategic direction for Toxicology/Pathology, BioAnalytical/DMPK, Biomarkers, and Clinical Pharmacology teams
  • Deliver high-quality data packages to regulatory authorities
  • Collaborate with cross-functional teams
  • Develop contingency plans and backup scenarios
  • Implement strategic plans for nonclinical operations
  • Adapt functional strategies to evolving scientific and regulatory landscapes
  • Identify, retain, and manage consultants and external subject matter experts
  • Foster collaborations with key opinion leaders and external partners
  • Support and coach subject matter experts in the authoring and preparation of CTD/CTA modules
  • Act as program lead for translational deliverables on selected key programs
  • Take on full project team leadership responsibilities for dedicated program(s)

ReCode Therapeutics offers a compelling work environment for those passionate about advancing the field of genetic medicine. The company's application of Selective Organ Targeting (SORT) lipid nanoparticle technology allows for precise delivery of genetic therapies beyond traditional liver targets, addressing rare diseases with groundbreaking approaches. Their focus on optimizing mRNA and gene correction further positions them as a forefront player in the biotechnology industry, making it an attractive place for innovative scientists and researchers looking to make a significant impact in medical science.

Company Stage

Series B

Total Funding

$521.8M

Headquarters

Menlo Park, California

Founded

2015

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

16%

2 year growth

95%